Researchers at UT MD Anderson Cancer Center have made significant breakthroughs in cancer treatment, including a promising new therapy for patients with specific EGFR-mutated lung cancer. Additionally, a study published in Science has provided new insights into the cell environment surrounding early breast cancers, shedding light on wh...
Scientists identify chimeric RNA molecules as essential in cellular health and disease, finding they play a wide variety of critical roles in vital cellular processes. Faulty chimeric RNA are often malfunctioning in breast cancer tumors, prompting new cancer treatments targeting specific chimeras.
A University of Houston researcher is developing a light-based technology to analyze tiny particles in the blood for molecular signs of liver cancer. The approach aims to detect the disease at its earliest stages and improve treatment options.
The invikafusp drug selectively expanded circulating and intratumoral Vβ6/Vβ10 T cells, peaking at optimal doses, with 59.3% disease control rates and 15% meaningful tumor shrinkage. The drug was well-tolerated with mostly mild to moderate treatment-related side effects.
A new treatment approach combining immunotherapy with targeted cancer drug enfortumab vedotin improves survival in patients with muscle-invasive bladder cancer. The treatment reduces the risk of death by 42% and cancer recurrence or progression by 49% in patients unable to receive standard chemotherapy.
Alliance Clinical Trials is advancing early detection, improving treatments, and enhancing survivorship for lung cancer patients. The organization is conducting seven active clinical trials focused on prevention, early detection, treatment, and survivorship.
The UVA Biotech Innovation Fund will support the SPARK Innovative Medicines program, helping to accelerate promising discoveries into new treatments and cures. The fund will provide long-term support for researchers to overcome the critical gap between discovery and clinical application.
Researchers analyzed 150,000 patient tumor samples to identify shared T cell receptors against cancer. The study found 11 families of receptors associated with common cancer antigens, offering a promising route for new cancer immunotherapies.
A triplet combination therapy regorafenib, chemotherapy, and immunotherapy shows promise against advanced gastric cancer, safely augmenting anti-tumor immune cells. The treatment, tested on 30 patients, reveals potential targets for future immunotherapeutic approaches.
Researchers identified protein DUSP4 that helps maintain cancer-fighting T cells' anti-tumour function, potentially improving CAR-T therapy against colorectal cancer. Lower DUSP4 levels in patients correlate with poorer overall survival.
The University of Texas M. D. Anderson Cancer Center hosted its fourth annual scientific symposium on frontiers of immunotherapy, featuring a panel discussion with five Nobel laureates and over 15 leading scientists and clinicians. The symposium focused on immune set points, exploring the regulatory mechanisms that determine immune sys...
Researchers at Vanderbilt-Ingram Cancer Center are investigating a novel approach to treating ovarian cancer by targeting proteins that help tumors evade the immune system. The grant supports development of an imaging approach to track treatment effectiveness and potentially identify patients most likely to benefit from treatment.
A new study published in Cell reveals that perforin, a protein made by T cells and NK cells, can induce ferroptosis in tumor cells, a previously unknown mechanism of cell death. This discovery could have significant implications for understanding how cancers are killed by immune cells and could lead to new avenues for immunotherapy.
Researchers found that high blood sugar can reprogram immune cells to better control tumor growth, increasing cancer-fighting abilities. This understanding could lead to new cancer immunotherapies that mimic these changes.
A novel antibody therapy empowers the immune system's tumor-fighting capabilities by targeting immune-suppressing T cells with greater precision. The therapy, which combines targeting CCR8 and activating CD3, promotes antitumor immunity in mice and nonhuman primates.
Cancers can evade chemotherapy by entering a 'zombie-like state' called premature senescence, which tricks the immune system into helping malignant cells. This phenomenon allows tumours to acquire extra oxygen and nutrients, making them more resistant to chemotherapy.
The NICHE-2 study demonstrates durable disease control with no disease recurrences in 111 patients with locally advanced mismatch repair-deficient colon cancer treated with short-course neoadjuvant immunotherapy. Circulating tumor DNA analysis reveals rapid molecular response to immunotherapy, with implications for treatment de-escalat...
A groundbreaking immunotherapy treatment for rectal cancer has received FDA approval, offering patients with locally advanced rectal cancer the possibility of eliminating their cancer without chemotherapy, radiation, or surgery. The treatment, developed through pioneering research at Memorial Sloan Kettering Cancer Center, has shown a ...
A research team at POSTECH developed an AI technology that analyzes genetic information from cancer patients to predict their response to immunotherapy. The study, published in npj Digital Medicine, outperformed biomarkers in predicting treatment response across four cancer types and six patient cohorts.
The Phase 1b FURTHER trial revealed that firmonertinib achieved durable antitumor activity in patients with EGFR PACC-mutated non-small cell lung cancer, with 43% and 68% objective response rates at 160mg and 240mg daily doses, respectively. Patients with complete clearance of EGFR PACC mutations from their blood experienced higher res...
UT MD Anderson Cancer Center has made significant advancements in cancer care, including the development of a covalent Werner helicase inhibitor, which showed promising antitumor efficacy in a Phase 1 trial. Additionally, a multicenter clinical trial found that tile-based radiation therapy improved tumor control and lowered the risk of...
Researchers at UCLA Health Jonsson Comprehensive Cancer Center used CRISPR screen to identify key molecular pathway driving T-cell exhaustion in cancer-fighting immune cells. Disabling the pathway, CRL5, allowed engineered immune cells to stay active longer and fight solid tumors more effectively in preclinical studies.
UChicago Medicine launches a groundbreaking clinical trial testing a new personalized cell therapy for advanced solid tumors, including ovarian cancer and melanoma. The treatment uses specially engineered T-cell receptors to detect hidden cancer proteins, expanding the number of cancers that can be targeted.
Researchers at IIT have developed a new technology that introduces a switch into CAR-T cells, controlling their activation in response to cancer cells. This switch allows for precise control over the therapeutic genes, reducing side effects and increasing effectiveness against melanoma and breast cancer.
Two UCLA-led studies reveal features of effective immune responses in glioblastoma and introduce a preclinical model that more closely mirrors the human disease. Long-term survivors showed evidence of a stronger immune response within their tumors, offering important clues for developing treatments.
Researchers at Penn State College of Medicine discovered that blocking protein PIK3C3/VPS34 raises levels of GD2 on the surface of tumor cells, making them easier to detect and more vulnerable to treatment. This increase also creates a hostile environment for cancer growth.
The review proposes co-designing oncolytic viruses and CAR cells to overcome solid tumor barriers, enabling a self-amplifying therapeutic system. Oncolytic viruses can be engineered to deliver payloads, expanding target recognition and maintaining CAR cell function.
The updated consensus recommendations provide a shared framework to support patient safety and consistency in clinical practice while continuing to build the evidence base. Key findings include careful patient selection, multidisciplinary care, and long-term follow-up as essential for CAR T-cell therapy in autoimmune diseases.
KRAS mutations define a distinct molecular subset of gastric adenocarcinoma with poor response to immunotherapy. KRAS inhibition combined with CTLA-4 blockade overcomes immunotherapy resistance by attenuating TGF-beta activity and impairing regulatory T cell function, sensitizing tumors to CTLA-4 immunotherapy.
Researchers have discovered that γδ T cells use adaptive immune receptors to drive rapid, innate-like responses to tissue stress, inflammation, and cancer. These cells rely on the receptor to maintain and mount rapid tissue surveillance responses, making them a promising candidate for next-generation cancer immunotherapies.
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
Researchers at UT MD Anderson Cancer Center have made significant breakthroughs in cancer treatment, developing a targeted antibody that improves outcomes for patients with advanced lung cancer who have faced treatment resistance. The treatment, which combines ivonescimab with chemotherapy, has been shown to extend disease control and ...
A Phase 1 clinical trial found that an investigational CAR-T therapy, anito-cel, led to high response rates and durable benefits in patients with relapsed/refractory multiple myeloma. Serious side effects were uncommon, and no delayed neurological complications were reported.
Weill Cornell Medicine has received significant funding for various cancer research projects, including precision medicine and drug target discovery. These initiatives aim to improve patient outcomes for challenging cancers, such as breast cancer and ovarian cancer. The funding supports innovative research approaches, including the stu...
Scientists found that the gene ZMYND8 drives T-cell exhaustion, revealing a new strategy to improve anti-tumor and anti-viral immune responses. Removing ZMYND8 improves anti-tumor and anti-viral responses on its own, and shows potential synergy in combination with immunotherapy.
Researchers at Bar-Ilan University and Weizmann Institute successfully engineered immune cells to recognize and attack cancer and viral targets. The enhanced T cells demonstrated stronger immune responses and greater cancer-killing ability, improving survival in mice.
Researchers identified a previously unknown pathway that prostate tumors leverage to suppress the immune system, reshaping the tumor microenvironment to resist treatment. Combining B7-H3-targeted therapy with MEK inhibition improved antitumor responses and prolonged survival in preclinical models of castration-resistant prostate cancer.
Researchers from City of Hope have developed a 'plug-and-play' CAR T technology that allows scientists to update engineered cancer-fighting immune cells after treatment. This technology, called meditope, enables the cells to adapt as tumors evolve, helping them to better control the cells and redirect them to attack different types of ...
Researchers identified a link between B cell activity and immunotherapy-related colitis, a common side effect of cancer treatments. Higher B cell levels before treatment were associated with increased colitis risk, and depleting B cells reduced colitis severity.
Researchers identify recurring states of tumor microenvironment that predict response to immunotherapy, finding that early treatment-induced changes can anticipate course of immune response
UCLA researchers are launching a phase 1/2 clinical trial to evaluate the safety and efficacy of JAK inhibitors in preventing immune checkpoint inhibitor-induced type 1 diabetes. The trial aims to test whether these drugs can protect insulin-producing cells in patients who develop diabetes after cancer immunotherapy.
The conference will explore next-generation biologics and immunotherapies, targeted protein modulation, and emerging therapies for oncogenic drivers. Experts will discuss the role of artificial intelligence in accelerating therapeutic development.
Researchers from Heidelberg University and Charité have identified a subgroup of CAR T cells that predict the success of low-dose therapies. The study found that the presence of highly functional CAR T cells and a healthy immune system before manufacturing begin are crucial for treatment success.
Researchers developed small molecules that activate macrophages to attack cancer cells, weakening the tumor's defenses against the immune system. The molecules, called Phagocytic Synapse Enhancers, were tested in cell cultures and animal models and showed promising results, slowing tumor growth and extending survival.
Cancer cells release natural antioxidants, such as Peroxiredoxin 1, to suppress immune-cell activity and prevent destruction. Removing this antioxidant production enhances the cancer's response to immunotherapy.
A modular nano-adaptor approach tunes T-cell activation to control CD3 activation and prevent toxicity, increasing therapeutic effectiveness in solid tumors. The platform has identified promising lead designs for multispecific nanoantibody configurations.
A new study shows that administering cell immunotherapy before surgery to remove a brain tumour is significantly more effective than administering it afterwards. CAR-T cells were able to neutralize tumor cells and immune suppression, leading to unprecedented durable tumour control.
A real-world observational study found no significant survival benefit from post-surgery immunotherapy in NSCLC patients with pathological complete response after neoadjuvant chemoimmunotherapy. The study suggests that these patients may already derive the maximum benefit from neoadjuvant therapy alone.
Researchers at Charité report significant success in treating severe rheumatoid arthritis with CD19 CAR T cells, reducing disease activity and promoting sustained remission in patients. The treatment targets disease-driving B cells, allowing the immune system to reset and eliminate harmful antibodies.
Researchers at the University of Massachusetts Amherst have been awarded $2.5 million to adapt their nanoparticle vaccine research to treat existing cancer. The prime-pull approach will deliver immune-activating medicines to both lymph nodes and tumors to create a robust immune response.
Researchers have developed an mRNA immunotherapy that eliminates pancreatic tumors in mice, achieving complete tumor responses and long-term disease-free periods. The treatment uses a cocktail of immune cytokine and tumor-associated antigen mRNAs, showing promise as a potential transformative treatment for pancreatic cancer.
Researchers at Nagoya University developed a new delivery vehicle for circular RNA (cirRNA) using a novel lipid nanoparticle, FL0445-LNP, which improves the stability and efficacy of mRNA-based therapeutics. The technology has potential applications in cancer vaccines, genome editing, and protein supplements.
Researchers at Pusan National University investigated how chronic environmental stress drives immune dysfunction in cold tumors, revealing a key driver of NK-cell maladaptation: the GDF15-AhR axis. This axis sustains activation of stress-sensing receptors, gradually exhausting NK cells and enabling immune escape.
The Alliance for Clinical Trials in Oncology emphasizes the significance of clinical trials in advancing breast cancer treatments and early detection. The organization's work has led to a 44% decline in breast cancer mortality rates among women since 1989.
Researchers developed a method to inhibit lipid nanoparticle migration into the liver by coating hepatic sinusoidal walls with polyethylene glycol. This coating reduced liver accumulation by several dozen times and increased protein expression in the spleen, promoting safer nanomedicine with lower dosages.
A study published in JAMA Otolaryngology–Head & Neck Surgery found that preoperative chemo-immunotherapy was more effective than immunotherapy alone in reducing tumor size in patients with head and neck cancer. The study analyzed data from 86 adults with head and neck cancer treated between July 2024 and March 2026, and showed that pat...
Research at UT MD Anderson Cancer Center has identified biomarkers to identify patients with resectable NSCLC who benefit most from perioperative immunotherapy. The center also found that the composition of donor cord blood may influence CAR NK cell therapy outcomes.
Scientists at Gladstone Institutes and UCSF discovered a pair of genetic edits that make CAR-T cells more effective against solid tumors. The new CRISPR screening platform enables the study of gene edits on CAR-T cells inside living mice, uncovering therapeutic targets previously missed in conventional cell culture systems.
Recent research found that D-serine accelerates gastric cancer growth by suppressing cytotoxic T-cell activity and promoting immunosuppressive macrophages. High serum D-serine concentrations were linked to ICI therapy resistance in patients, suggesting its potential as a biomarker for disease progression.
Cancer cells' ability to evade the immune system is linked to changes in their surrounding environment, including nearby nutrients and conditions. Researchers discovered that altering these factors can thin the cancer cell's protective sugar coating, allowing the immune system to recognize and eliminate them.